Insight

Julie Hallet: 1 of 3 PNETs potentially over-treated especially small PNETs in expert centre

Photo taken from Julie Hallet/LinkedIn

Aug 12, 2024, 12:22

Julie Hallet: 1 of 3 PNETs potentially over-treated especially small PNETs in expert centre

Julie Hallet, Chair, Equity Diversity and Inclusion Group at IHPBA, shared a post by Giovanni Marchegiani, at

“1 of 3 PNETs potentially over-treated especially small PNETs in expert centre (higher elsewhere) Same OS over vs appropriate treatment 25% overtreated pts have unnecessary morbidity.

We can harm patients NET MCC over treatment One of my fave this year.“

Quoting Giovanni Marchegiani’s post:

“Surgery for non functioning pancreatic neuroendocrine tumors.

Are we harming our patients.

Almost 400 resected P-NET with path and FU analysis %

Inadequate treatment (34% potential overtreatment)

Size only reliable predictor.“

Critical appraisal of the adequacy of surgical indications for non-functioning pancreatic neuroendocrine tumours

Authors: Stefano Partelli, Anna Battistella, Valentina Andreasi, Francesca Muffatti, Domenico Tamburrino, Nicolò Pecorelli, Stefano Crippa, Gianpaolo Balzano, and Massimo Falconi.

For more information.

Source: Julie Hallet/X and Giovanni Marchegiani/X

Anna Battistella cancer Gianpaolo Balzano Giovanni Marchegiani Julie Hallet Massimo Falconi OncoDaily Oncology PNETs Stefano Crippa Stefano Partelli Valentina Andreasi

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer